(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr22.00 | 8.25% | 19.84% |
| EQUASENS (EQS.PA) | €51.30 | 2.7% | 23.04% |
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 0.95% | 7.27% |
| BIOMERIEUX (BIM.PA) | €102.25 | 0.87% | 8.73% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
8.25% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.32. Meaning, the purchaser of the share is investing kr17.32 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
More news about VISTIN PHARMA.
2. EQUASENS (EQS.PA)
2.7% Forward Dividend Yield and 23.04% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.2.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 16.03. Meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.04%.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €51.30 at 22:30 EST, way below its 52-week high of €78.20 and way above its 52-week low of €42.95.
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.20%, a negative 0.29%, and a positive 2.27%.
EQUASENS’s highest amplitude of average volatility was 2.44% (last week), 1.91% (last month), and 2.27% (last quarter).
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 2, 2024, the estimated forward annual dividend rate is 1.25 and the estimated forward annual dividend yield is 2.7%.
More news about EQUASENS.
3. EUROFINS SCIENT. (ERF.PA)
0.95% Forward Dividend Yield and 7.27% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 3, 2024, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 0.95%.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €59.08 at 22:30 EST, under its 52-week high of €62.10 and way higher than its 52-week low of €39.47.
Volatility
EUROFINS SCIENT.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.82%, a positive 0.34%, and a positive 1.79%.
EUROFINS SCIENT.’s highest amplitude of average volatility was 1.20% (last week), 1.37% (last month), and 1.79% (last quarter).
More news about EUROFINS SCIENT..
4. BIOMERIEUX (BIM.PA)
0.87% Forward Dividend Yield and 8.73% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.01.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 33.97. Meaning, the purchaser of the share is investing €33.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Moving Average
BIOMERIEUX’s value is above its 50-day moving average of €93.63 and above its 200-day moving average of €98.02.
Yearly Top and Bottom Value
BIOMERIEUX’s stock is valued at €102.25 at 22:30 EST, under its 52-week high of €108.90 and way higher than its 52-week low of €84.54.
Volatility
BIOMERIEUX’s last week, last month’s, and last quarter’s current intraday variation average was 0.19%, 0.21%, and 0.92%.
BIOMERIEUX’s highest amplitude of average volatility was 0.63% (last week), 0.70% (last month), and 0.92% (last quarter).
More news about BIOMERIEUX.
